Last reviewed · How we verify
Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration (AFLIWEST)
Age-related macular degeneration is a leading cause of visual impairment in older adults. In its exudative form, repeated intravitreal injections of anti-VEGF agents are required to control disease activity. A new formulation of aflibercept at a higher dose (8 mg) has been developed with the aim of extending the interval between injections. This multicenter retrospective real-world observational study will evaluate the effect of switching to aflibercept 8 mg in patients with refractory or dependent exudative age-related macular degeneration. Clinical data collected during routine care will be analyzed to compare injection intervals, treatment burden, visual outcomes, anatomical outcomes, and safety before and after the switch.
Details
| Lead sponsor | Nantes University Hospital |
|---|---|
| Status | NOT_YET_RECRUITING |
| Enrolment | 100 |
| Start date | 2026-02 |
| Completion | 2026-10 |
Conditions
- Exudative Age-Related Macular Degeneration
Interventions
- aflibercept 8 mg
Primary outcomes
- Change in intravitreal injection interval — From 12 months before switch to 12 months after switch to aflibercept 8 mg
Difference in the number of weeks between intravitreal anti-VEGF injections before switching to aflibercept 8 mg and after 12 months of treatment with aflibercept 8 mg, or at the last observed interval in case of switch to another molecule.